Literature DB >> 19500572

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.

Ana Muñoz1, Thomas Carlsson, Elisabetta Tronci, Deniz Kirik, Anders Björklund, Manolo Carta.   

Abstract

5-HT1 receptor agonists have been shown to reduce abnormal involuntary movements (AIMs) in the rat and monkey models of L-DOPA-induced dyskinesia. Different mechanisms have been proposed to underlie this effect. Activation of pre-synaptic 5-HT1 receptors has been suggested to inhibit dysregulated release of dopamine from the serotonin terminals, and thus, abnormal activation of striatal dopamine receptors. Activation of post-synaptic 5-HT1 receptors expressed in non-serotonergic neurons in different brain areas, by contrast, has been shown to result in decreased glutamate and GABA release, which may also contribute to the antidyskinetic effect. To unveil the relative contribution of these mechanisms, we have investigated the effect of increasing doses of 5-HT1A and 5-HT1B receptor agonists on AIMs induced by either L-DOPA or apomorphine. In contrast to L-DOPA-induced AIMs, which were dampened already at low doses of 5-HT1 agonists, reduction of apomorphine-induced AIMs required higher doses. Removal of the serotonin innervation suppressed L-DOPA-induced AIMs, but neither affected apomorphine-induced AIMs nor the inhibiting effect of 5-HT1 agonists on AIMs induced by the direct dopamine agonist, suggesting that such effect is independent on activation of pre-synaptic 5-HT1 receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19500572     DOI: 10.1016/j.expneurol.2009.05.033

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  23 in total

Review 1.  Genetic therapy for the nervous system.

Authors:  William J Bowers; Xandra O Breakefield; Miguel Sena-Esteves
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

Review 2.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

Review 3.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

Review 4.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 5.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

6.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 7.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

8.  Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.

Authors:  J S Dileep Kumar; Ramin V Parsey; Suham A Kassir; Vattoly J Majo; Matthew S Milak; Jaya Prabhakaran; Norman R Simpson; Mark D Underwood; J John Mann; Victoria Arango
Journal:  Brain Res       Date:  2013-02-27       Impact factor: 3.252

9.  Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

Authors:  D Lindenbach; N Palumbo; C Y Ostock; N Vilceus; M M Conti; C Bishop
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

10.  Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Authors:  Melissa M Conti; Corinne Y Ostock; David Lindenbach; Adam A Goldenberg; Elias Kampton; Rich Dell'isola; Aaron C Katzman; Christopher Bishop
Journal:  Neuropharmacology       Date:  2013-09-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.